Amphotericin B lipid complex: Recent progress

Drugs of Today

Volumn 32, Issue SUPPL. G, 1996, Pages 33-42

  Karyotakis, Nicholas C ^a   Anaissie, Elias J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; LIPOSOME;

AREA UNDER THE CURVE; COMPLEX FORMATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; MYCOSIS; NEPHROTOXICITY; PHARMACOKINETICS; REVIEW;

EID: 0029846765     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Utz, J.P., Louria, D.B., Feder, N., Emmons, G.W., McCullough, N.B. Report of clinical studies on use of amphotericin in patients with systemic fungal diseases. In: Antibiotics Annual 1957-1958. Proceedings of the Fifth Annual Symposium on Antibiotics. New York Medical Encyclopedia 1958, 65-70.
2. Seabury, I.J., Dascomb, H.E. Experience with amphotericin B. Ann NY Acad Sci 1960, 89: 202-20.
3. Gallis, H.A., Drew, R.H., Pickard, W.W. Ampho-tericin B: 30 years of clinical experience. Rev Infect Dis 1990, 12: 308-29.
4. Hammond, S.M. Biological activity of polyene antibiotics. Prog Med Chem 1977, 14: 105-79.
5. Ghannoum, M.A., Filler, S.G., Ibrahim, A.S., Fu, Y., Edwards, J.E. Jr. Modulation of interactions of Candida albicans and endothelial cells by fluconazole and amphotericin B. Antimicrob Agents Chemother 1992, 36: 2239-44.
6. Sokol-Anderson, M.L., Brajtburg, J., Medoff, G. Amphotericin B-induced oxidative damage and killing of Candida albicans. J Infect Dis 1986, 154: 76-83.
7. Bangham, A.D. Liposomes: The Babraham connection. Chem Phys Lipids 1993, 64: 275-85.
8. Ostro, M.J., Cullis, P.R. Use of liposomes as injectable-drug delivery systems. Amer J Hosp Pharm 1989, 46: 1576-87.
9. New, R.R, Chance, M.L., Heath, S. Anti-leishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J Antimicrob Chemother 1981, 8: 371-81.
10. Graybill, J.R., Craven, P.C., Taylor, R.L., Williams, D.M., Magee, W.E. Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis 1982, 145: 748-52.
11. López-Berestein, G., Hopfer, R.L., Mehta, R., Mehta, K., Hersh, E.M., Juliano, R.L. Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J Infect Dis 1984, 150: 278-83.
12. López-Berestein, G., Fainstein, V., Hopfer, R., Mehta, K., Sullivan, M.P., Keating, M. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: A preliminary study. J Infect Dis 1985, 151: 704-10.
13. López-Berestein, G., Bodey, G.P., Frankel, L.S., Mehta, K. Treatment of hepato-splenic candidiasis with liposomal-amphotericin B. J Clin Oncol 1987, 5: 310-7.
14. Janoff, A.S., Boni, L.T., Popescu, M.C. et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA 1988, 85: 6122-6.
15. Mehta, R., López-Berestein, G., Hopfer, R., Mills, K., Juliano, R. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta 1984, 770: 220-34.
16. ™): A molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 1993, 3: 451-72.
17. Wasan, K.M., Brazeau, G.A., Keyhani, A., Hayman, A., López-Berestein, G. Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob Agents Chemother 1993, 37: 246-50.
18. Hopfer, R.L., Mills, K., Mehta, R., López-Berestein, G., Fainstein, V., Juliano, R.L. In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B. Antimicrob Agents Chemother 1984, 25: 387-9.
19. Mitsutake, K., Kohno, S., Miyazaki, Y. et al. In vitro and in vivo antifungal activities of liposomal amphotericin B, and amphotericin B lipid complex. Mycopathologia 1994, 128: 13-7.
20. Olsen, S.J., Swerdel, M.R., Blue, B., Clark, J.M., Bonner, D.P. Tissue distribution of amphotericin B lipid complex in laboratory animals. J Pharm Pharmacol 1991, 43: 831-5.
21. Clark, J.M., Whitney, R.R., Olsen, S.J. et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991, 35: 615-21.
22. Lee, J., Allende, M., Amantea, M. Pharmacokinetics and efficacy of amphotericin B lipid complex (ABLC) against chronic disseminated candidiasis in rabbits. 31st Intersci Conf Antimicrob Agents Chemother 1992, Abst 579.
23. ABELCET. Product Monograph. The Liposome Company, Inc. 1996, April.
24. Whitney, R.R., Kunselman, L., Clark, J.M., Bonner, D.P. Efficacy of amphotericin B lipid complex (ABLC) in cryptococcal meningitis in normal and immunocompromised mice. 29th Intersci Conf Antimicrob Agents Chemother 1989, Abst 166.
25. Clemons, K.V., Stevens, D.A. Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis. Antimicrob Agents Chemother 1991, 35: 2144-6.
26. Clemons, K.V., Stevens, D.A. Efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine coccidioidomycosis. J Antimicrob Chemother 1992, 30: 353-63.
27. Perfect, J.R., Wright, K.A. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. J Antimicrob Chemother 1994, 33: 73-81.
28. Allendoerfer, R., Yates, R.R., Sun, S.H., Graybill, J.R. Comparison of amphotericin B lipid complex with amphotericin B and SCH 39304 in the treatment of murine coccidioidal meningitis. J Med Vet Mycol 1992, 30: 377-84.
29. Kan, V.L., Bennett, J.E., Amantea, M.A. et al. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in healthy male volunteers. J Infect Dis 1991, 164: 418-21.
30. Gracella, D., Echevarría, J., Summerill, R. et al. Pharmacokinetics of amphotericin B following administration as amphotericin B lipid complex (ABLC) or Fungizone (FZ) in adults with mucocutaneous leishmaniasis. 33rd Intersci Conf Antimicrob Agents Chemother 1993, Abst 1439.
31. Gregoriadis, G. The carrier potential of liposomes in biology and medicine. New Engl J Med 1976, 295: 704-10, 765-70.
32. Gregoriadis, G. (Ed.). Liposomes as Drug Carriers. Recent Trends and Progress. Wiley: Chichester 1988.
33. deWit, S., Rossi, C., Duchateau, J., Braitman, A., Gupta, R., Clumeck, N. Safety, tolerance and immunomodulatory effect of amphotericin B lipid complex (ABLC) in HIV infected subjects (S). Phase I/II study. 31st Intersci Conf Antimicrob Agents Chemother 1991, Abst 288.
34. Sharkey, P.K., Graybill, J.R., Johnson, S.E. et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996, 22: 315-21.
35. Llanos-Cuentas, A., Cieza, J., Echevarría, J. et al. The safety and tolerance of amphotericin B lipid complex (ABLC) vs. amphotericin B desoxycholate (Fungizone[AB]) in patients with mucocutaneous leishmaniasis (MCL). 32nd Intersci Conf Antimicrob Agents Chemother 1992, Abst 234.
36. Sharkey, P.K., Lipke, R., Renteria, A. et al. Amphotericin B lipid complex (ABLC) in treatment (Rx) of coccidioidomycosis (C). 31st Intersci Conf Antimicrob Agents Chemother 1991, Abst 742.
37. Walsh, T.J., Hiemenz, J.W., Seibel, N., Anaissie, E.J. Amphotericin B lipid complex in the treatment of 228 cases of invasive mycoses. 34th Intersci Conf Antimicrob Agents Chemother 1994, Abst M69.
38. Hiemenz, J.W., Lister, J., Anaissie, E.J. et al. Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: Histological control comparison with amphotericin B. Blood 1995, 86 (Suppl. 1): Abst 3383.
39. Anaissie, E.J., Ramphal, R. Efficacy and safety of amphotericin B lipid complex (ABLC) in the treatment of patients with life-threatening fusariosis. 34th Intersci Conf Antimicrob Agents Chemother 1994, Abst M87.
40. ®) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: A prospective, randomized, multicenter trial. 35th Intersci Conf Antimicrob Agents Chemother 1995, Abst LM21.